Urogenital System

Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Urogenital System Resource Center

Welcome to the MPR Urogenital System Resource Center, where you will find everything you need to make informed clinical decisions.

Drug Monographs

Click on the subcategory below to find drug monographs for that particular area.

News

AUA: Male Pattern Baldness Predictive of Prostate Cancer

Male baldness is associated with prostate cancer, with more severe balding patterns more strongly associated with cancer.

US Task Force Recommends Against PSA-Based Screening

The US Preventive Services Task Force (USPSTF) recommends against the use of the prostate-specific antigen (PSA)-based screening for men in the general US population.

ASCO: Abiraterone Tolerated in High-Risk Prostate Cancer

For men with localized high-risk prostate cancer, neoadjuvant androgen deprivation therapy with abiraterone acetate (AA) plus leuprolide acetate (LHRHa) is well tolerated and has good pathological complete/near complete response (pCR/near pCR) rates.

Lack of Post-MI Discharge Advice Hinders Sexual Activity

Less than half of patients who suffer an acute myocardial infarction (AMI) receive instruction regarding resuming sexual activity on hospital discharge, with those who do not receive instruction more likely to report loss of sexual activity.

ECO: Normalizing Testosterone in Men Linked to Weight Loss

Parenterally administered testosterone injections in overweight or obese men with low testosterone levels lead to significant weight loss and improved waist circumference, blood pressure, and metabolic parameters.

DUTOPROL

5/21/2012

AstraZeneca Pharmaceuticals

Pharmacological Class: Cardioselective β₁-blocker + diuretic.

Active Ingredient(s): Metoprolol succinate extended-release, hydrochlorothiazide; 25/12.5mg, 50/12.5mg, 100/12.5mg; tablets.

Indication: Hypertension.

KORLYM

5/14/2012

Corcept Therapeutics

Pharmacological Class: Cortisol receptor blocker.

Active Ingredient(s): Mifepristone 300mg; tabs.

Indication: To control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and have failed surgery or are not candidates for surgery.

VORAXAZE

5/7/2012

BTG International

Pharmacological Class: Carboxypeptidase enzyme.

Active Ingredient(s): Glucarpidase; 1,000 Units/vial; lyophilized powder for IV injection after reconstitution; preservative-free.

Indication: Treatment of toxic plasma methotrexate (MTX) concentrations (>1 micromole per liter) in patients with delayed MTX clearance due to impaired renal function.